secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001193125-25-245102
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns
------------------------------------------------------------------------------

- Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.
- Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.
- President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.
- Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/0001193125-25-245102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-20251020.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer